StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

Aktis Oncology gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Aktis Oncology

Aktis Oncology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Aktis Oncology figures

See a number that looks wrong?